Nanodrug delivery systems for metabolic chronic liver diseases: advances and perspectives - Supplementary information

Nanomedicines are revolutionizing healthcare as recently demonstrated by the Pfizer/BioNTech and

Moderna COVID-2019 vaccines, with billions of doses administered worldwide in a safe manner.

Nonalcoholic fatty liver disease is the most common noncommunicable chronic liver disease, posing a

major growing challenge to global public health. However, due to unmet diagnostic and therapeutic

needs, there is great interest in the development of novel translational approaches. Nanoparticle-based

approaches offer novel opportunities for efficient and specific drug delivery to liver cells, as a step

toward precision medicines. In this review, the authors highlight recent advances in nanomedicines for

the generation of novel diagnostic and therapeutic tools for nonalcoholic fatty liver disease and related

liver diseases.